Skip Navigation

This Article
Right arrow Print PDF (6695K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Li, Y.-P.
Right arrow Articles by Stashenko, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y.-P.
Right arrow Articles by Stashenko, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1995, Vol. 23, No. 24 5064-5072
© 1995


Articles

Characterization of a silencer element in the first exon of the human osteocalcin gene

Yi-Ping Li*, Wel Chen and Philip Stashenko

Department of Cylokine Biology, Forsyth Dental Center 140 The Fenway, Boston, MA 02115, USA

*To whom correspondence should be addressed

Received July 14, 1995. Accepted November 5, 1995.

Osteocalcin, the major non-collagenous protein In bone, is transcribed in osteoblasts at the onset of extracellular matrix mineralization. In this study it was demonstrated that sequences located in the first exon of the human osteocalcin gene possess a differentiation- related osteocalcin silencer element (OSE). Osteocalcin was rendered transcribable In UMR-106 cells and proliferating normal osteoblasts after deletion of the -3 to +51 region. Site-specific mutagenesis of this region revealed that a 7 bp sequence (TGGCCCT) (+29 to +35) is critical for silencing function. Mobility shift assays demonstrated that a nuclear factor bound to the OSE. The OSE binding protein was present in proliferating normal pre-osteoblasts and In UMR-106 and ROS 17/2.8 osteosarcoma cells, but was absent from post-proliferative normal osteoblasts. The binding protein was inhibited by fragments containing the +29/+35 sequence, but not by other promoter fragments or by the consensus oligomers of unrelated nuclear factors AP-1 and Sp1. DNase I footprinting demonstrated that the OSE binding-protein protected the +17 to +36 portion of the first exon, consistent with the results of mapping studies and competitive mobility shift assays. It is hypothesized that this silencer is activated by complexing of the OSE binding protein to the OSE during the osteoblast proliferation stage and that the OSE binding protein is down-regulated at the onset of extracellular matrix mineralization.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
EndocrinologyHome page
J.-L. Zhu, C.-I Pao, E. Hunter Jr., K.-w. M. Lin, G.-j. Wu, and L. S. Phillips
Identification of Core Sequences Involved in Metabolism-Dependent Nuclear Protein Binding to the Rat Insulin-Like Growth Factor I Gene
Endocrinology, October 1, 1999; 140(10): 4761 - 4771.
[Abstract] [Full Text]


Home page
HypertensionHome page
T. Voigtlander, D. Ganten, and M. Bader
Transcriptional Regulation of the Rat Renin Gene by Regulatory Elements in Intron I
Hypertension, January 1, 1999; 33(1): 303 - 311.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
B. Frenkel, C. Capparelli, M. van Auken, D. B. , J. Bryan, J. L. Stein, G. S. Stein, and J. B. Lian
Activity of the Osteocalcin Promoter in Skeletal Sites of Transgenic Mice and during Osteoblast Differentiation in Bone Marrow-Derived Stromal Cell Cultures: Effects of Age and Sex
Endocrinology, May 1, 1997; 138(5): 2109 - 2116.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.